Correlation of the different genotype groups of eSNPs to <i>ARLTS1</i> RNA expression levels.

<p>A, rs2075610; B, rs7997737; C, rs1543513; D, rs9568232; E, rs9568354; F, rs1886014; G, rs7337547; H, rs7995192; I, rs9562905; J, rs2580189; K, rs2532975; L, rs1262781; M, rs1262774 and N, rs17074618.</p

Schematic diagram showing the genomic locations of eSNPs gathered by eQTL analysis in PCa patients.

<p>The gene symbols are as follows: <i>CYSLTR2</i> (cysteinyl leukotriene receptor 2), <i>FNCD3A</i> (fibronectin type III domain containing 3A), <i>MLNR</i> (motilin receptor), <i>CDADC1</i> (cytidine and dCMP deaminase domain containing 1), <i>CAB39L</i> (calcium binding protein 39-like), <i>SETDB2</i> (SET domain, bifurcated 2/<i>CLLD8</i>), <i>PHF11</i> (PHD finger protein 11/NY-REN-34 antigen), <i>RCBTB1</i> (regulator of chromosome condensation [RCC1] and BTB [POZ] domain containing protein 1/<i>CLLD7</i>), <i>ARLTS1</i> (/<i>ARL11</i>, ADP-ribosylation factor-like 11), <i>EBPL</i> (emopamil binding protein-like), <i>KPNA3</i> (karyopherin alpha 3, importin alpha 4), <i>SPRYD7</i> (SPRY domain containing 7<i>/C13orf1</i>, chromosome open reading frame 1), <i>MIR3613</i> (microRNA 3613), <i>TRIM13</i> (tripartite motif containing 13), <i>KCNRG</i> (potassium channel regulator), <i>MIR-15A</i> and <i>MIR16-1</i> (microRNA genes 15a and 16-1) and <i>DLEU2</i> (deleted in lymphocytic leukemia 2).</p

Relative <i>ARLTS1</i> RNA expression from PCa patients and healthy controls.

<p>Relative <i>ARLTS1</i> RNA expression was determined by RNA sequencing analysis. Columns represent means of individuals; bars represent SD.</p

Clinicopathologic findings at diagnosis of the PCa patients used in RNA sequencing (n = 84).

<p>Clinicopathologic findings at diagnosis of the PCa patients used in RNA sequencing (n = 84).</p

<i>ARLTS1</i> Co-expression signatures from tumor specimens and cell lines.

*<p>Bonferroni correction.</p>#<p>Benjamini Hohchberg multiple testing correction.</p

Expression profile of <i>ERBB3</i> in pediatric healthy and cancer tissues.

<p><b>A</b>) Body-wide expression profile of the <i>ERBB3</i> gene across the database. Each dot represents the expression of <i>ERBB3</i> in one sample. Anatomical origins of each sample are marked in color bars below the gene plot. The <i>ERBB3</i> gene is highly expressed in malignant connective and muscular tissue samples (green dots). <b>B</b>) Box plot analysis of the <i>ERBB3</i> gene expression levels across a variety of pediatric cancer samples. <i>ERBB3</i> is particularly highly expressed in alveolar rhabdomyosarcomas. NOS, not otherwise specified.</p

Expression profile of <i>VEGFC</i> in pediatric healthy and cancer tissues.

<p><b>A</b>) Body-wide expression profile of the <i>VEGFC</i> gene across the database. Each dot represents the expression of <i>VEGFC</i> in one sample. Anatomical origins of each sample are marked in color bars below the gene plot. The <i>VEGFC</i> gene is highly expressed in samples originating from malignant connective or muscular tissue (green dots). The ten green dots forming a separate group with high <i>VEGFC</i> expression all represent samples from Ewing’s sarcoma. <b>B</b>) Box plot analysis of the <i>VEGFC</i> gene expression levels across a variety of pediatric cancer samples. <i>VEGFC</i> is particularly highly expressed in Ewing’s sarcoma. NOS, not otherwise specified.</p

Expression profile of <i>EPHA2</i> in pediatric healthy and cancer tissues. A

<p>) Body-wide expression profile of the <i>EPHA2</i> gene across the database. Each dot represents the expression of <i>EPHA2</i> in one sample. Anatomical origins of each sample are marked in color bars below the gene plot. The <i>EPHA2</i> gene is highly expressed in malignant connective and muscular tissue samples (green dots). <b>B</b>) Box plot analysis of the <i>EPHA2</i> gene expression levels across a variety of pediatric cancer samples. <i>EPHA2</i> is particularly highly expressed in osteosarcoma and Ewing’s sarcoma. NOS, not otherwise specified.</p

Expression and function of ErbB3 in rhabdomyosarcoma.

<p>(<b>A</b>) Western analysis of ErbB3 expression in RD cells transfected or not with a plasmid encoding ErbB3 or an empty vector control (lanes 1–3), or with <i>ERBB3</i>-targeting or control siRNA (lanes 4–5). Membranes were reblotted with anti-actin to control loading. (<b>B–D</b>) Immunohistochemical analysis of ErbB3 expression in normal adult human stomach (<b>B</b>) and in two samples representing pediatric alveolar rhabdomyosarcoma (<b>C</b>,<b>D</b>). (<b>E</b>,<b>F</b>) MTT proliferation analysis of the effect of <i>ERBB3</i> overexpression (<b>E</b>) or siRNA-mediated <i>ERBB3</i> down-regulation on the growth of RD cell transfectants. Expression of ErbB3 in the transfectants is shown in (<b>A</b>). *, <i>P</i><0.001 when compared to control. Scale bar in (<b>B–D</b>), 100 µm.</p

Hierarchial clustering of validated therapeutic target genes in rhabdomyosarcomas and Ewing’s sarcomas.

<p>The red boxes illustrate mRNA expression levels exceeding the mean expression per gene in the analyzed tissues, whereas the blue boxes illustrate mRNA expression levels lower than the mean expression per gene. The number of samples analyzed per tissue type is given in parentheses.</p